Observational studyThe Journal of international medical research2023
HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population.
Observational study in The Journal of international medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Is the metabolic dysfunction-associated steatotic liver disease a predictor of chronic kidney disease?World journal of nephrology · 2026Article
- Selenoprotein P deficiency in MASLD: association with insulin resistance and liver fibrosis: a prospective case-control study.BMC gastroenterology · 2026Article
- Epidemiological features of pediatric nonalcoholic fatty liver disease in China.Diabetology & metabolic syndrome · 2026Article
- A ubiquitous organophosphate flame retardant disrupts energy and glucose homeostasis in mice.Ecotoxicology and environmental safety · 2026Article
- Article
- Association between HOMA-IR and metabolic dysfunction-associated steatohepatitis in U.S. adults with MASLD.Metabolism open · 2025Article
- Association of incidence of colorectal polyp with markers of insulin resistance and other related factors: a cross-sectional study.Scientific reports · 2025Article
- The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and the risk of insulin resistance: results from the NHANES 2003-2016.BMC endocrine disorders · 2025Article
- The correlation between insulin-like growth factor 1 and left ventricular mass index in obese children.BMC endocrine disorders · 2025Article
- Frequency of insulin resistance among non-diabetic patients with non-alcoholic fatty liver disease using HOMA-IR: an experience of a tertiary care hospital in Karachi, Pakistan.BMC gastroenterology · 2025Article
- The association of screen time with childhood obesity and metabolic status: a mediation analysis of cardiorespiratory fitness.Frontiers in endocrinology · 2025Article
- Article
- Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content.Gastro hep advances · 2025Review
- Comparison of Non-invasive Liver Fat Scoring Systems as Markers of Metabolic Dysfunction-Associated Liver Disease.Cureus · 2024Article
- Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease.Cardiovascular diabetology · 2024Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to investigate the correlation between homeostasis model assessment of insulin resistance (HOMA-IR) and non-alcoholic fatty liver disease (NAFLD) in the non-diabetic population and establish its diagnostic efficacy.
methodsThis observational study involved participants divided into NAFLD and non-NAFLD groups, and baseline data were analyzed. Univariate and multivariate logistic regression analyses were used to correlate HOMA-IR with the risk of NAFLD. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic efficacy of HOMA-IR for NAFLD. Subgroup analyses of non-obese individuals were performed.
resultsOverall, 2234 non-diabetic participants were included. The HOMA-IR was significantly higher in the NAFLD group than in the non-NAFLD group. Multivariate logistic regression analysis showed that HOMA-IR was a strong and independent risk factor for NAFLD after correcting for confounding factors. The area under the ROC curve (AUC) value of HOMA-IR for predicting NAFLD was 0.792. In the non-obese non-diabetic population, HOMA-IR was an independent risk factor for increased risk of lean NAFLD after correcting for confounding factors. The AUC value of HOMA-IR for predicting lean NAFLD was 0.770.
conclusionsHOMA-IR is independently associated with the risk of NAFLD in the non-diabetic and non-obese non-diabetic populations and has good diagnostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.